Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Yonsei Medical Journal ; : 809-816, 2016.
Article in English | WPRIM | ID: wpr-26896

ABSTRACT

Human respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory tract infection, such as bronchiolitis, bronchitis, or pneumonia, in both infants and the elderly. Despite the global burden of diseases attributable to RSV infection, no clinically approved vaccine is available, and a humanized monoclonal antibody for prophylaxis is not readily affordable in developing countries. There are several hurdles to the successful development of RSV vaccines: immune-vulnerable target populations such as premature infants, pregnant women, and immunocompromised people; safety concerns associated with vaccine-enhanced diseases; repeated infection; and waning memory. To develop successful strategies for the prevention of RSV infection, it is necessary to understand the protective and pathologic roles of host immune responses to RSV infection. In this review, we will summarize the positive and negative relationship between RSV infection and host immunity and discuss strategies for the development of the first successful RSV vaccine.


Subject(s)
Humans , Immunity , Immunocompromised Host , Respiratory Syncytial Virus Infections/immunology , Respiratory Syncytial Virus Vaccines , Respiratory Syncytial Viruses/physiology
3.
Actual. pediátr ; 6(1): 44-7, mar. 1996. ilus
Article in Spanish | LILACS | ID: lil-190427

ABSTRACT

La bronquiolitis por virus sincitial respiratorio (USR) es una enfermedad de las vías aéreas pequeñas, caracterizada por inflamación y obstrucción de los bronquiolos. El VSR fue aislado por primera vez en 1995, pertenece a la familia de los paramixovirus. Es clara la presentación epidérmica anual que compromete especialmente a lactantes pequeños. La tasa de infección por VSR durante el primer año de vida alcanza el 69 por ciento y el 83 por ciento durante el segundo. La mortalidad en niños previamente sanos es del 0.005 por ciento al 0.002 por ciento; en pacientes hospitalizados es del 1 al 3 por ciento. Aunque se ha descrito que la infección por VSR no altera la función cardíaca en pacientes con corazón sano, se encuentra en la literatura informes aislados al respecto; a continuación presentamos un caso de un paciente con bronquiolitis por VSR, en el que se documentó miocarditis por este mismo germen.


Subject(s)
Humans , Infant , Male , Bronchiolitis, Viral/diagnosis , Bronchiolitis, Viral/drug therapy , Bronchiolitis, Viral/etiology , Bronchiolitis, Viral/history , Bronchiolitis, Viral/microbiology , Bronchiolitis, Viral/nursing , Myocarditis/classification , Myocarditis/drug therapy , Myocarditis/epidemiology , Myocarditis/history , Myocarditis/microbiology , Myocarditis/nursing , Myocarditis/physiopathology , Respiratory Syncytial Viruses/chemistry , Respiratory Syncytial Viruses/isolation & purification , Respiratory Syncytial Viruses/pathogenicity , Respiratory Syncytial Viruses/physiology
SELECTION OF CITATIONS
SEARCH DETAIL